CAREDX INC (CDNA) Stock Price, Forecast & Analysis
NASDAQ:CDNA • US14167L1035
CDNA Key Statistics, Chart & Performance
The current stock price of CDNA is 18.35 USD. In the past month the price decreased by -8.02%. In the past year, price decreased by -15.03%.
CDNA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CDNA. When comparing the yearly performance of all stocks, CDNA is a bad performer in the overall market: 74.36% of all stocks are doing better.
CDNA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CDNA. CDNA has an excellent financial health rating, but there are some minor concerns on its profitability.
CDNA Financial Highlights
Over the last trailing twelve months CDNA reported a non-GAAP Earnings per Share(EPS) of 0.59. The EPS increased by 9.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.97% | ||
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| Debt/Equity | 0 |
CDNA Forecast & Estimates
14 analysts have analysed CDNA and the average price target is 24.48 USD. This implies a price increase of 33.41% is expected in the next year compared to the current price of 18.35.
For the next year, analysts expect an EPS growth of 54.76% and a revenue growth 11.48% for CDNA
CDNA Ownership
CDNA Latest News, Press Relases and Analysis
CDNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.78 | 397.113B | ||
| AMGN | AMGEN INC | 17.3 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.63 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.2 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.38 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.45 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.59 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.97 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CDNA
Company Profile
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.
Company Info
CAREDX INC
8000 Marina Blvd, 4th Floor
Brisbane California CALIFORNIA 94080 US
CEO: Reginald Seeto
Employees: 644
Phone: 14152872300
CAREDX INC / CDNA FAQ
What does CAREDX INC do?
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.
What is the stock price of CAREDX INC today?
The current stock price of CDNA is 18.35 USD. The price decreased by -2.5% in the last trading session.
Does CDNA stock pay dividends?
CDNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CDNA stock?
CDNA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Where is CAREDX INC (CDNA) stock traded?
CDNA stock is listed on the Nasdaq exchange.
How is the market expecting CDNA stock to perform?
14 analysts have analysed CDNA and the average price target is 24.48 USD. This implies a price increase of 33.41% is expected in the next year compared to the current price of 18.35.
Can you provide the sector and industry classification for CAREDX INC?
CAREDX INC (CDNA) operates in the Health Care sector and the Biotechnology industry.